Pediatric Heart Institute, Joe DiMaggio Children's Hospital, Hollywood, Florida.
Baylor College of Medicine, Texas Children's Hospital Austin Specialty Care, Austin, Texas.
Pediatr Transplant. 2020 May;24(3):e13673. doi: 10.1111/petr.13673. Epub 2020 Feb 17.
To correlate gene expression profiling scores obtained by AlloMap with cardiac hemodynamics, cardiac allograft vasculopathy (CAV), and echocardiographic parameters in asymptomatic, rejection-free pediatric heart transplant (HT) recipients.
Single-institution retrospective study of 210 AlloMap scores obtained concomitantly with cardiac catheterization and echocardiogram from 55 children during follow-up after cardiac transplantation.
The median age at HT was 5.1 years (range, 0.9-14.1), with 29 males and 26 females. AlloMap scores were high in <2 years vs ≥2 years of age at the time of HT (P = .001), and trending higher with time after HT (R = .04, P = .004). There was no significant difference in scores between ACR grades 0 and 1R or CAV. There was mild to modest correlation of AlloMap scores with the mean right atrial pressure (P = .002), and pulmonary capillary wedge pressure (P = .02), but no correlation was found with LV SF% (P = .3), LV EF% (P = .5), or RV FAC % (P = .8).
Our study provides preliminary data that the AlloMap score must be studied carefully before it can be used in children, particularly in those under 2 years of age. Monitoring of serial scores for each patient could potentially reflect changes in allograft performance that may determine indications for catheterization and biopsy which needs to be validated in future studies.
通过 AlloMap 获得的基因表达谱评分与心脏血流动力学、心脏移植血管病 (CAV) 和无症状、无排斥反应的儿科心脏移植 (HT) 受者的超声心动图参数相关。
对 55 例心脏移植后随访期间同时进行心导管检查和超声心动图检查的 210 例 AlloMap 评分进行单中心回顾性研究。
HT 时的中位年龄为 5.1 岁(范围,0.9-14.1 岁),男性 29 例,女性 26 例。HT 时年龄<2 岁的 AlloMap 评分高于≥2 岁(P=.001),且随时间推移呈上升趋势(R=0.04,P=.004)。ACR 分级 0 级和 1R 级或 CAV 之间的评分无显著差异。AlloMap 评分与平均右心房压(P=.002)和肺毛细血管楔压(P=.02)有轻度至中度相关性,但与 LV SF%(P=.3)、LV EF%(P=.5)或 RV FAC%(P=.8)无相关性。
我们的研究提供了初步数据,即在儿童中使用 AlloMap 评分之前,必须仔细研究,特别是在 2 岁以下的儿童中。对每个患者的系列评分进行监测可能反映移植物功能的变化,这可能决定进行导管插入术和活检的指征,这需要在未来的研究中得到验证。